Valneva SE (INRLF) Research

Valneva SE operates as a specialized biopharmaceutical entity, primarily focused on the creation and commercialization of preventative vaccines for infectious diseases where effective treatments are currently lacking. Its existing range of vaccines for international travelers includes IXIARO, an inactivated, Vero cell culture-based immunization designed to actively protect against Japanese encephalitis. Another key product is DUKORAL, an oral vaccine intended to prevent diarrhea caused by Vibrio cholera and/or the heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also developed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva is advancing VLA15, a Lyme disease vaccine candidate that has successfully completed Phase II clinical trials. Furthermore, VLA1553, a candidate vaccine against the chikungunya virus, is currently undergoing Phase III clinical evaluation. Valneva distributes its products globally, with a market presence spanning the United States, Canada, Germany, Austria, the Nordic region, the United Kingdom, other European countries, and various international territories. The company has established significant strategic collaborations, including a partnership with Pfizer, Inc. to jointly develop and commercialize its Lyme disease vaccine. It also collaborates with Instituto Butantan on the development, manufacturing, and marketing of a single-dose chikungunya vaccine. Founded in 1998, Valneva SE is headquartered in Saint-Herblain, France.

Open Valneva SE (INRLF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.